Your article on rational drug design (Features: research, THES , October 26) gave a good summary of current thinking about chemical modelling, given increasing costs in moving drugs through the development process. Only a small percentage of drugs make it from the laboratory bench to preclinical or phase-one trials, let alone go on to be proved efficacious and end up on the pharmacists' shelf.
Mark Lipscombe
Project manager
Origin Pharmaceutical Services Ltd
Register to continue
Why register?
- Registration is free and only takes a moment
- Once registered, you can read 3 articles a month
- Sign up for our newsletter
Subscribe
Or subscribe for unlimited access to:
- Unlimited access to news, views, insights & reviews
- Digital editions
- Digital access to THE’s university and college rankings analysis
Already registered or a current subscriber? Login